Ingredient Guide
Benfotiamine: Benefits, Dosage, and What the Research Says
A fat-soluble vitamin B1 derivative with significantly higher bioavailability than standard thiamine -- here is what decades of clinical research actually show.
Written by Jessica Medson
Benfotiamine is a fat-soluble synthetic derivative of thiamine (vitamin B1) whose unique chemistry allows it to be absorbed far more efficiently than standard water-soluble thiamine supplements -- one pharmacokinetic study in healthy volunteers found plasma thiamine concentrations roughly 1,147% greater after benfotiamine compared with an equivalent dose of thiamine hydrochloride. Once absorbed, it is converted to thiamine diphosphate (ThDP), the active coenzyme form of B1, which activates the enzyme transketolase and diverts glucose metabolites away from pathways that generate damaging advanced glycation end products (AGEs). Clinical research suggests benfotiamine may support peripheral nerve comfort in the short term and shows preliminary signals for cognitive support, though longer-term trials have produced mixed results on objective neurological measures.
What Is Benfotiamine?
Benfotiamine -- also called S-benzoylthiamine O-monophosphate or, informally, fat-soluble vitamin B1 -- is a synthetic, lipid-soluble derivative of thiamine originally developed in Japan in the late 1950s. It belongs to a class of thiamine analogs called allithiamines, compounds that share a structural feature (an open thiazole ring) enabling them to move through fatty cell membranes far more readily than the water-soluble thiamine found in most supplements and foods.
Standard thiamine hydrochloride and thiamine mononitrate enter intestinal cells via saturable active transporters. Once those transporters are saturated -- which occurs quickly at moderate doses -- absorption plateaus no matter how much more you take. Benfotiamine bypasses this bottleneck: its lipophilic benzoyl group allows passive diffusion directly through the intestinal epithelium, producing a steep, dose-responsive rise in blood thiamine levels.3
A pharmacokinetic crossover study in healthy volunteers quantified this advantage directly: plasma thiamine area-under-the-curve (AUC) was 1,147% that of thiamine hydrochloride following an equivalent oral dose of benfotiamine, and thiamine diphosphate (ThDP) levels in red blood cells were approximately 196% of those achieved with the reference compound.1 An earlier study found that benfotiamine achieved superior cellular uptake and greater transketolase stimulation even when given at only 40% of the dose of a water-soluble comparator.2
Benfotiamine has been prescribed in Germany and other European countries for decades under trade names such as Milgamma-N for diabetic neuropathy. In the United States it is available as an over-the-counter dietary supplement. It is not a stimulant, hormone, or drug, and it does not directly supply energy.
How Does Benfotiamine Work?
After absorption, benfotiamine is rapidly de-phosphorylated and converted in blood and liver first to free thiamine and then to thiamine diphosphate (ThDP), the biologically active coenzyme form of vitamin B1.6 ThDP is an essential cofactor for at least three key enzymes in cellular energy metabolism:
- Pyruvate dehydrogenase complex -- converts pyruvate to acetyl-CoA, the gateway to the citric acid cycle
- Alpha-ketoglutarate dehydrogenase -- a rate-limiting step in the Krebs cycle; reduced activity is observed in Alzheimer's disease brains
- Transketolase -- a core enzyme in the pentose phosphate pathway
The transketolase-AGE connection
The transketolase link is central to benfotiamine's proposed therapeutic actions. When blood glucose is chronically elevated, excess glucose metabolites accumulate -- including glyceraldehyde-3-phosphate and fructose-6-phosphate -- and react non-enzymatically with proteins and lipids to form advanced glycation end products (AGEs). AGEs accumulate in nerves, blood vessel walls, and the kidneys, where they bind to their receptor (RAGE) and trigger oxidative stress and inflammation that contribute to diabetic complications.5
By raising intracellular ThDP and activating transketolase, benfotiamine channels these glycolytic intermediates back into the pentose phosphate pathway, reducing the metabolic precursors available for AGE formation.5 Preclinical and review-level evidence also identifies direct antioxidant and anti-inflammatory properties of benfotiamine that appear to operate through pathways independent of its coenzyme function, including modulation of NF-kappaB signaling and reduction of oxidative stress markers in glial cells.12
It is important to note that much of the mechanistic evidence comes from cell culture and animal models. The degree to which these mechanisms translate to meaningful outcomes in healthy, non-diabetic humans is not established by current evidence.
Benfotiamine and Peripheral Nerve Health
The most extensively studied application of benfotiamine in humans is supporting peripheral nerve health in people with diabetes-related nerve involvement (diabetic polyneuropathy). This condition affects an estimated 50% of individuals with long-standing diabetes and is characterized by pain, burning, tingling, and numbness that typically begins in the feet and hands.
What the research shows
The BEDIP study (Haupt et al., 2005) was a three-week randomized, double-blind, placebo-controlled pilot trial that enrolled 40 inpatients (ages 18-70) with type 1 or type 2 diabetes and existing polyneuropathy. Participants received either 200 mg benfotiamine daily or placebo. The benfotiamine group showed a statistically significant improvement in neuropathy score (p = 0.029) versus placebo, with pain specifically reaching significance (p = 0.041). No adverse effects attributable to benfotiamine were observed in either group.7
Longer-term trials have produced more cautious findings. A 24-month double-blind, placebo-controlled trial published in Diabetes Care (Fraser et al., 2012) enrolled 67 patients with type 1 diabetes randomized to either 300 mg/day benfotiamine or placebo. Although whole-blood thiamine and ThDP concentrations rose markedly in the treatment group (both p < 0.001), researchers found no statistically significant differences in peripheral nerve function measures or soluble inflammatory biomarkers at the end of the trial.9
The most recent dedicated neuropathy trial is the BOND study (Ziegler et al., 2026), a 12-month randomized, double-blind, placebo-controlled trial in 60 patients with type 2 diabetes and symptomatic polyneuropathy. Participants received 600 mg/day benfotiamine (300 mg twice daily) or placebo. The primary endpoint -- corneal nerve fiber length, a sensitive marker of small nerve fiber integrity -- showed no significant difference between groups (p = 0.760). Among secondary endpoints, only the Neuropathy Symptom Score showed a non-significant trend favoring benfotiamine (p = 0.098). Free thiamine levels in the benfotiamine group rose more than 35-fold versus the small rise seen with placebo. The compound was well-tolerated throughout.13
What this means overall: Short-term trials suggest benfotiamine may support nerve comfort, but two rigorous longer-term trials have not demonstrated significant effects on objective neurophysiological measures. Sample sizes in all completed trials have been relatively small, limiting the statistical power to detect modest effects. The evidence is best characterized as preliminary and encouraging for symptom support, not conclusive for disease modification.
Benfotiamine and Cognitive Support
A separate line of research explores whether benfotiamine might support cognitive function, motivated by two observations: (1) the brains of people with Alzheimer's disease show reduced activity of ThDP-dependent enzymes, including alpha-ketoglutarate dehydrogenase; and (2) elevated AGEs are found in the Alzheimer's brain and may accelerate neurodegeneration.12
What the research shows
A randomized, placebo-controlled Phase IIa clinical trial (Gibson et al., 2020) enrolled 70 adults with amnestic mild cognitive impairment or mild dementia due to Alzheimer's disease. Participants received either benfotiamine (300 mg twice daily, 600 mg/day total) or placebo for 12 months.
- The primary outcome, the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), showed 43% less decline in the benfotiamine group than in the placebo group, but this difference did not reach statistical significance (p = 0.125).
- The Clinical Dementia Rating (CDR) -- a composite measure of cognition and everyday functioning -- showed worsening that was 77% lower in the benfotiamine group, and this difference was statistically significant (p = 0.034).
- Plasma AGEs increased significantly in the placebo group but were significantly attenuated in the benfotiamine group (p = 0.044), suggesting target engagement.
- No adverse events were attributed to benfotiamine. Serum thiamine increased 161-fold in treated participants.11
A review of thiamine and benfotiamine's neuroprotective mechanisms (Sambon et al., 2021) highlights the compound's antioxidant and anti-inflammatory activity in neuronal and glial cells as additional mechanistic support for future cognitive research.12
Important caveat: The Gibson et al. study is a Phase IIa pilot trial (n=70) designed to test safety and generate preliminary efficacy signals, not to provide definitive proof of benefit. The primary outcome (ADAS-Cog) did not reach significance. A larger, adequately powered Phase IIb trial (BenfoTeam, NCT06223360) is ongoing and will be necessary before any firm conclusions about benfotiamine and cognitive health can be drawn. Research suggests potential; it does not establish efficacy in the general population.
Benfotiamine and Vascular Health
Preclinical data and one controlled human trial suggest benfotiamine may help maintain normal endothelial function when the vascular system is challenged by a high-AGE dietary load -- a common occurrence in diets heavy in processed, heat-treated foods.
What the research shows
A randomized crossover study (Stirban et al., 2006) enrolled 13 adults with type 2 diabetes and challenged them with a meal deliberately high in AGEs (a standard McDonald's meal was used as the AGE-rich test meal in the original protocol). Under placebo conditions, the high-AGE meal produced a 35.1% impairment in flow-mediated dilation (FMD, a measure of artery flexibility) and a 60.0% reduction in reactive hyperemia (a measure of microvascular blood flow) within hours. Markers of oxidative stress rose significantly. Benfotiamine pretreatment (1,050 mg/day for 3 days before the meal) completely prevented both FMD impairment and the reactive hyperemia decline, and significantly blunted oxidative stress biomarker increases.8
A contrasting 12-week randomized controlled trial in 82 patients with type 2 diabetes and microalbuminuria (Alkhalaf et al., 2012) gave participants 900 mg/day benfotiamine or placebo. Despite confirmed improvement in thiamine status, the study found no significant reductions in plasma or urinary AGEs, markers of endothelial dysfunction (including sVCAM-1, sICAM-1, and E-selectin), or inflammatory biomarkers.10
The divergence between these trials likely reflects differences in context: acutely challenging the vascular system with an exogenous AGE load (Stirban) versus baseline circulating AGE levels in established nephropathy (Alkhalaf). The preclinical mechanistic rationale for vascular benefit remains coherent; the human clinical picture is mixed, and larger trials are needed.
Safety, Side Effects, and Interactions
General safety profile: Benfotiamine has been well-tolerated in all published randomized controlled trials to date, including studies lasting up to 24 months at doses between 300 mg and 1,050 mg per day. No serious adverse events have been attributed to it in these trials. Reviews of its pharmacology note an absence of documented toxicity at therapeutic doses.69
Potential side effects
- Mild gastrointestinal symptoms (nausea, loose stools) have been occasionally reported at higher doses but are uncommon.
- Because benfotiamine is fat-soluble and accumulates in tissues more readily than water-soluble thiamine, theoretical concerns about excessive tissue accumulation exist, though no toxicity from this mechanism has been reported in human studies at supplement doses.
Pregnancy and breastfeeding
Adequate data on the safety of benfotiamine supplementation during pregnancy or lactation are not available. Standard thiamine is an essential nutrient during pregnancy, but benfotiamine as a supplement has not been formally studied in pregnant or breastfeeding individuals. Consult your healthcare provider before use.
Drug interactions
- Diabetes medications and insulin: Benfotiamine may theoretically influence glucose metabolism through its transketolase-activating effects. People using insulin, metformin, sulfonylureas, or other blood-sugar-lowering medications should monitor glucose levels carefully and discuss supplementation with their prescribing clinician before starting.
- Thiamine-affecting medications: Certain diuretics (particularly loop diuretics such as furosemide) can deplete thiamine. Benfotiamine may help maintain thiamine status in this context, but this has not been systematically studied and should be discussed with a provider.
- Alcohol use disorder / Wernicke's encephalopathy risk: While benfotiamine may support thiamine status, acute Wernicke's encephalopathy (a thiamine-deficiency neurological emergency common in alcohol use disorder) requires high-dose intravenous thiamine -- oral benfotiamine supplementation is not an established or appropriate substitute in that acute setting.
Who should not take benfotiamine without medical guidance
- Individuals with kidney disease (thiamine metabolism may differ)
- People already taking multiple B-vitamin supplements at high doses
- Anyone with a known allergy to thiamine or benfotiamine compounds
Benfotiamine Dosage: What Clinical Trials Have Used
No official recommended dietary allowance (RDA) exists for benfotiamine as a supplement. The doses below reflect what has been used in published human trials; they are not prescriptions. Always follow product labeling and consult a healthcare provider for personalized guidance.
| Goal | Typical Dose | Timing | Notes |
|---|---|---|---|
| Short-term nerve symptom support (research context) | 200 mg/day | Single or divided dose with meals | Dose used in the 3-week BEDIP RCT (Haupt et al., 2005); statistically significant neuropathy score improvement observed |
| Longer-term nerve support (research context, type 1 diabetes) | 300 mg/day | Once or twice daily with meals | Used in Fraser et al. 2012 (24-month RCT); markedly raised thiamine/ThDP levels but did not significantly improve nerve function vs placebo |
| Longer-term nerve support (research context, type 2 diabetes) | 600 mg/day (300 mg twice daily) | Divided doses with meals, morning and evening | BOND study dose (Ziegler et al., 2026); well-tolerated for 12 months; primary neurophysiological endpoint not met |
| Cognitive support (research context, early Alzheimer's disease) | 600 mg/day (300 mg twice daily) | Divided doses with meals | Gibson et al. 2020 Phase IIa trial; CDR score worsened significantly less vs placebo (p=0.034); 161-fold rise in serum thiamine confirmed |
| Vascular protection after high-AGE meal (research context) | 1,050 mg/day for 3 days | Divided doses with meals | Short-term pretreatment protocol in Stirban et al. 2006; completely prevented endothelial dysfunction in type 2 diabetics |
Doses above 600 mg/day have limited long-term safety data. Start at the lower end of the range and discuss ongoing use with a healthcare provider, especially if you have diabetes or take medications.
What the Evidence Shows at a Glance
Summary of key human trials and their findings. Evidence tiers: Tier A = human RCT or pharmacokinetic study; Tier B = human observational or review.
| Outcome | Key Study (Design, N, Duration) | Result | Evidence Strength |
|---|---|---|---|
| Plasma thiamine bioavailability vs HCl | Xie et al. 2014 (PK crossover, healthy volunteers) | AUC 1,147% of thiamine HCl; red blood cell ThDP ~196% of HCl | Tier A - Human PK study |
| Bioavailability at 40% of comparator dose | Bitsch et al. 1991 (crossover, N=10 healthy men) | Superior plasma and erythrocyte levels despite lower dose; greater transketolase stimulation | Tier A - Human PK study |
| Neuropathy symptom score (short-term) | BEDIP: Haupt et al. 2005 (RCT, N=40, 3 weeks) | Statistically significant improvement vs placebo (p=0.029); pain reduced (p=0.041) | Tier A - RCT |
| Peripheral nerve function (24-month) | Fraser et al. 2012 (RCT, N=67, type 1 DM) | No significant difference in nerve conduction or inflammatory markers vs placebo | Tier A - RCT |
| Corneal nerve fiber length (12-month) | BOND: Ziegler et al. 2026 (RCT, N=60, type 2 DM) | No significant difference vs placebo (p=0.760); neuropathy symptom trend only (p=0.098) | Tier A - RCT |
| Clinical Dementia Rating in early AD | Gibson et al. 2020 (Phase IIa RCT, N=70, 12 months) | CDR worsened 77% less in benfotiamine group (p=0.034); ADAS-Cog trend not significant | Tier A - Phase IIa RCT (preliminary) |
| Endothelial function after AGE-rich meal | Stirban et al. 2006 (crossover RCT, N=13, type 2 DM) | Completely prevented FMD impairment and reactive hyperemia decline vs placebo | Tier A - RCT crossover |
| Plasma/urinary AGEs in nephropathy | Alkhalaf et al. 2012 (RCT, N=82, 12 weeks) | No significant reduction in AGE markers or endothelial dysfunction markers vs placebo | Tier A - RCT |
DM = diabetes mellitus; FMD = flow-mediated dilation; ThDP = thiamine diphosphate; AUC = area under the curve (pharmacokinetic measure of total exposure).
Frequently Asked Questions
What is benfotiamine good for?
Benfotiamine is most studied for supporting peripheral nerve health in people with diabetes-related neuropathy and, more recently, for potential cognitive support in early Alzheimer's disease. Its high bioavailability makes it useful whenever the goal is raising intracellular thiamine diphosphate levels more efficiently than standard vitamin B1 supplements can. Evidence is strongest for short-term nerve symptom support; longer-term neurophysiological benefits remain unproven.
How much benfotiamine should I take per day?
Human trials have used doses ranging from 200 mg/day (short-term neuropathy support) to 600 mg/day (longer-term neuropathy and cognitive studies) and up to 1,050 mg/day for brief vascular-protection protocols. Most supplement products provide 150-300 mg per capsule. There is no established RDA for benfotiamine. Start at the lower end of the studied range and consult a healthcare provider for personalized guidance.
Is benfotiamine safe?
Published randomized controlled trials lasting up to 24 months at doses of 300-900 mg/day have not reported serious adverse events attributable to benfotiamine. Mild gastrointestinal side effects are occasionally noted at higher doses. People with diabetes taking blood-sugar medications, pregnant or breastfeeding individuals, and those with kidney disease should consult a healthcare provider before use.
Does benfotiamine work for diabetic neuropathy?
Results are mixed. A 3-week RCT found statistically significant improvements in neuropathy symptom scores with 200 mg/day benfotiamine. However, two larger, longer trials (12 and 24 months) did not find significant improvements in objective nerve fiber or conduction measures. Short-term symptom support is plausible; long-term disease modification has not been demonstrated in current evidence.
How is benfotiamine different from regular vitamin B1?
Standard thiamine (vitamin B1 hydrochloride or mononitrate) is water-soluble and absorbed through saturable membrane transporters -- meaning absorption plateaus quickly. Benfotiamine is fat-soluble and passively diffuses through intestinal cell membranes. One pharmacokinetic study found benfotiamine produced plasma thiamine levels more than 11 times higher than an equivalent dose of thiamine hydrochloride, along with roughly double the active coenzyme (ThDP) in red blood cells.
Can benfotiamine help with nerve pain?
Research suggests it may support nerve comfort in the short term. The BEDIP study (a 3-week RCT in 40 people with diabetic polyneuropathy) found statistically significant reductions in pain scores with 200 mg/day benfotiamine. However, longer trials have not consistently confirmed this benefit on objective measures. Benfotiamine is not a replacement for medical treatment of neuropathic pain.
Does benfotiamine help with memory or Alzheimer's disease?
A Phase IIa randomized trial (70 participants, 12 months) found that the Clinical Dementia Rating score -- a composite of cognition and daily function -- worsened 77% less in the benfotiamine group versus placebo (p=0.034). This is an encouraging early signal, but this was a small pilot study and the primary cognitive outcome did not reach significance. A larger Phase IIb trial is ongoing. The evidence is preliminary.
What are benfotiamine's side effects?
Benfotiamine has been generally well-tolerated in clinical trials up to 24 months. The most commonly reported side effects at higher doses are mild and gastrointestinal in nature (nausea, loose stools). No serious adverse events have been attributed to benfotiamine in published trials. As with any supplement, interactions with medications or individual sensitivities are possible.
Can I take benfotiamine if I have diabetes and am on medication?
Speak with your prescribing clinician first. Benfotiamine activates transketolase and may influence glucose metabolism pathways. If you take insulin, metformin, sulfonylureas, or other blood-glucose-lowering medications, there is a theoretical -- though not well-documented clinically -- risk of additive effects on blood sugar. Several clinical trials in diabetic patients did not report hypoglycemia, but personalized medical guidance is important.
Is benfotiamine the same as thiamine or vitamin B1?
Benfotiamine is related to but chemically distinct from thiamine. It is a synthetic prodrug: after absorption it converts to free thiamine and then to thiamine diphosphate (the active coenzyme). You can think of it as a delivery system that gets more vitamin B1 into cells than ordinary thiamine supplements. It is not found naturally in food in significant amounts, unlike thiamine itself.
Shop Benfotiamine
HealthFare Benfotiamine supplements
Scientific References
- 1.Xie F, Cheng Z, Li S, Liu X, Guo X, Yu P, Gu Z Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride. Journal of Clinical Pharmacology. 2014. PubMed: 24399744Clinical (RCT / meta-analysis)
- 2.Bitsch R, Wolf M, Moller J, Heuzeroth L, Gruneklee D Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Annals of Nutrition and Metabolism. 1991. PubMed: 1776825Clinical (RCT / meta-analysis)
- 3.Loew D Pharmacokinetics of thiamine derivatives especially of benfotiamine. International Journal of Clinical Pharmacology and Therapeutics. 1996. PubMed: 8929745Human observational
- 4.Greb A, Bitsch R Comparative bioavailability of various thiamine derivatives after oral administration. International Journal of Clinical Pharmacology and Therapeutics. 1998. PubMed: 9587048Clinical (RCT / meta-analysis)
- 5.Balakumar P, Rohilla A, Krishan P, Solairaj P, Thangathirupathi A The multifaceted therapeutic potential of benfotiamine. Pharmacological Research. 2010. PubMed: 20188835Human observational
- 6.Bozic I, Lavrnja I Thiamine and benfotiamine: Focus on their therapeutic potential. Heliyon. 2023. PubMed: 38034619Human observational
- 7.Haupt E, Ledermann H, Kopcke W Benfotiamine in the treatment of diabetic polyneuropathy -- a three-week randomized, controlled pilot study (BEDIP study). International Journal of Clinical Pharmacology and Therapeutics. 2005. PubMed: 15726875Clinical (RCT / meta-analysis)
- 8.Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C, Kleesiek K, Mueller-Roesel M, Koschinsky T, Uribarri J, Vlassara H, Tschoepe D Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care. 2006. PubMed: 16936154Clinical (RCT / meta-analysis)
- 9.Fraser DA, Diep LM, Hovden IA, Nilsen KB, Sveen KA, Seljeflot I, Hanssen KF The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care. 2012. PubMed: 22446172Clinical (RCT / meta-analysis)
- 10.Alkhalaf A, Kleefstra N, Groenier KH, Bilo HJ, Gans RO, Heeringa P, Scheijen JL, Schalkwijk CG, Navis GJ, Bakker SJ Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One. 2012. PubMed: 22792314Clinical (RCT / meta-analysis)
- 11.Gibson GE, Luchsinger JA, Cirio R, Chen H, Franchino-Elder J, Hirsch JA, et al. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. Journal of Alzheimer's Disease. 2020. PubMed: 33074237Clinical (RCT / meta-analysis)
- 12.Sambon M, Wins P, Bettendorff L Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine. International Journal of Molecular Sciences. 2021. PubMed: 34063830Human observational
- 13.Ziegler D, et al. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy: a randomized, placebo-controlled, double-blind clinical trial (BOND study). BMJ Open Diabetes Research and Care. 2026. PubMed: 41571333Clinical (RCT / meta-analysis)